Helix BioPharma Corp. experienced a significant uptick in stock price, closing up over 14% in yesterday's trading session.
In a notable turn of events, Helix BioPharma Corp. saw its stock price increase by 14.53% yesterday, closing at CA$2.05. This surge marks a positive shift for the company, which has been navigating a challenging financial landscape.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$110.75M
52W high
$5.40
52W low
$1.10
1W change
+3.57%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 72.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+72.4% Upside
Current Price
C$1.45
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
77.8%
Annualized
90-Day Vol
56.9%
Annualized
Trend (90d)
+36.3%
Annualized drift
90d Mean
C$1.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.51 | C$1.16 – C$1.98 |
| 60 trading days | C$1.58 | C$1.08 – C$2.31 |
| 90 trading days | C$1.65 | C$1.04 – C$2.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on Helix BioPharma Corp. as the recent surge may indicate growing confidence in its future prospects, especially in the context of its ongoing capital-raising efforts.
Stock Price Increased by 14.53%
Helix BioPharma's market cap now sits at approximately CA$156.6 million following the price surge.
Bull case
The recent rise in Helix BioPharma's stock could show that investors are feeling more confident. This optimism might be fueled by the company's strategic efforts to raise capital and advance its therapeutic programs. If Helix successfully navigates its financing agreements, this positive sentiment could continue.
Bear case
Despite the recent gains, Helix BioPharma still faces challenges, such as a history of net losses and the ongoing need for capital to support its operations. Investors should be cautious about whether this price increase is sustainable.
Advertisement
Recent Performance Overview
Helix BioPharma Corp.'s stock closed at CA$2.05 yesterday, marking a significant gain of 14.53%. This performance comes amid a backdrop of strategic financial maneuvers aimed at bolstering the company's capital position.
Market Reaction and Investor Sentiment
The sharp increase in Helix BioPharma's stock price may suggest a positive shift in investor sentiment. With ongoing efforts to secure funding, including recent announcements regarding capital raising agreements, investors are showing renewed interest in the company.
Looking Ahead
As Helix BioPharma continues to pursue its therapeutic programs, investors should monitor upcoming developments closely. The company's ability to sustain this momentum will depend on its execution of strategic initiatives and market conditions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
